StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Amortization of intangible assets in cost of sales by Quarter

Amortization of intangible assets in cost of sales ($M) ($M)

QuarterlyAnnual

Eli Lilly Amortization of intangible assets in cost of sales: $125M in Q2 2026, up 2.6% from a year earlier.

Latest, Q2 2026
125
Period ended Jun 30, 2026
Change on a year earlier
+2.6%
122 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
14
Documents cited below

Where the Q2 2026 figure comes from

“|| Amortization of intangible assets (Cost of sales) (1) | 125 | 122 | 253 | 245”

Source: Earnings Release (Form 8-K FY2026Q2 EX-99.1) (filed 2026-08-05) ↗

Reported in Form 8-K Non-GAAP Reconciliation Schedules.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAmortization of intangible assets in cost of sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026125+2.6%Earnings Release (Form 8-K FY2026Q2 EX-99.1) (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026128+4.1%Earnings Release (Form 8-K FY2026Q1 EX-99.1) (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025124-8.6%Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗
Q3 2025Sep 30, 2025119-14.5%Earnings Release (Form 8-K FY2025Q3 EX-99.1) (filed 2025-10-30) ↗
Q2 2025Jun 30, 2025122-12.4%Earnings Release (Form 8-K FY2025Q2 EX-99.1) (filed 2025-08-07) ↗
Q1 2025Mar 31, 2025123-11.6%Earnings Release (Form 8-K FY2025Q1 EX-99.1) (filed 2025-05-01) ↗
Q4 2024Dec 31, 2024136+5.1%Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗
Q3 2024Sep 30, 2024139+11.5%Earnings Release (Form 8-K FY2024Q3 EX-99.1) (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024139+10.0%Earnings Release (Form 8-K FY2024Q2 EX-99.1) (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024139+10.6%Earnings Release (Form 8-K FY2024Q1 EX-99.1) (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023129+3.9%Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 2023125+0.7%Earnings Release (Form 8-K FY2023Q3 EX-99.1) (filed 2023-11-02) ↗
Q2 2023Jun 30, 2023126+4.2%Earnings Release (Form 8-K FY2023Q2 EX-99.1) (filed 2023-08-08) ↗
Q1 2023Mar 31, 2023126-38.5%Earnings Release (Form 8-K FY2023Q1 EX-99.1) (filed 2023-04-27) ↗
Q4 2022Dec 31, 2022124–Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2022Sep 30, 2022124–Earnings Release (Form 8-K FY2023Q3 EX-99.1) (filed 2023-11-02) ↗

Cite this data

StockData. (2026). Eli Lilly Amortization of intangible assets in cost of sales ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/gm-amort-intang

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.